EA Series Trust’s Charles River Laboratories CRL Stock Holding History

EA Series Trust’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$511K	Buy	+2,430	New	+$483K	0.02%	815

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

EA Series Trust's CRL Position: Q2 2023 in Review

EA Series Trust opened a new position in Charles River Laboratories (CRL) in Q2 2023: 2,430 shares worth $511K. The stake represents 0.02% of the portfolio and ranks #815 among its holdings.

612 funds tracked by Wall St. Rank hold CRL as of Q2 2023.

EA Series Trust held 2,430 shares of Charles River Laboratories worth $511K as of Q2 2023.
Charles River Laboratories was a new EA Series Trust position in Q2 2023.
Charles River Laboratories made up 0.02% of EA Series Trust's portfolio in Q2 2023, its #815 holding.
612 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2023.

Based on EA Series Trust's 13F filing for Q2 2023, filed 27 Jul 2023.